AEGiS-WSJ: Agouron's AIDS Drug Races Against Time and Titans: Trials Must Start Quickly, Before Competition Grows and Patient Pool Shrinks Wall Street JournalImportant note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Click here to return to Wall Street Journal main menu




DonateNow



Agouron's AIDS Drug Races Against Time and Titans: Trials Must Start Quickly, Before Competition Grows and Patient Pool Shrinks

The Wall Street Journal - December 20, 1995
Rhonda L. Rundle, Staff Reporter of The Wall Street Journal

SAN DIEGO -- Agouron Pharmaceuticals Inc. is in an unusual race to get its new AIDS drug through human trials. If it doesn't do so before rival drugs flood the market, it will be more difficult to test Agouron's compound on untreated patients, making it harder to prove any competitive advantages.

In the dash to commercialize a new class of AIDS drugs -- known as protease inhibitors -- Agouron's entry is in fourth place behind leader Hoffmann-La Roche Inc.'s Invirase, which was approved recently. Invirase is likely to be followed in 1996 by products from Merck & Co. and Abbott Laboratories Inc.

Hope that the drugs may be able to slow the spread of the deadly human immunodeficiency virus within patients, and thus extend life by perhaps several years, has generated
951220
WJ951206

Copyright © 1995 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .